Dabigatran: all 149 studies that test it

Page 2 of 2. Open to participants first (6), then studies with results posted, then the rest; newest registration first within each.

• Investigation on Appropriate Duration of Dabigatran Use After Catheter Ablation for Paroxysmal Atrial Fibrillation in Patients With Low Thromboembolic RiskStatus unknownNCT02313584Phase 3
• Dabigatran Following Transient Ischemic Attack and Minor StrokeCompletedNCT02295826Phase 2
• Resolution of Left Atrial-Appendage Thrombus - Effects of Dabigatran in Patients With AFTerminatedNCT02256683Phase 2
• Relative Bioavailability of Single Doses of Dabigatran Etexilate in Healthy VolunteersCompletedNCT02173717Phase 1
• Safety and Pharmacokinetics of Quinidine Alone and in Combination With Dabigatran EtexilateCompletedNCT02171624Phase 1
• Relative Bioavailability of Dabigatran Etexilate Capsules With and Without Quinidine Sulfate Tablets and to Measure the Effect of Quinidine on the Absorption of Fexofenadine in Healthy Male and Female VolunteersTerminatedNCT02171546Phase 1
• Relative Bioavailability of Dabigatran and Diclofenac After Dabigatran Etexilate and Diclofenac Single Dose Alone or Following Concomitant Multiple Oral Administrations in Healthy Male and Female VolunteersCompletedNCT02171507Phase 1
• Relative Bioavailability of Dabigatran and Digoxin in Healthy Male and Female VolunteersCompletedNCT02171052Phase 1
• Relative Bioavailability of Dabigatran and Atorvastatin in Healthy Male and Female VolunteersCompletedNCT02171039Phase 1
• Bioavailability of Dabigatran and Amiodarone After Multiple Oral Administrations of Dabigatran Etexilate With or Without Amiodarone as Single Dose in Healthy Male and Female VolunteersCompletedNCT02171026Phase 1
• Safety, Pharmacokinetics and Pharmacodynamics After Multiple Oral Doses of BIBR 1048 MS Capsule in Healthy Japanese Male SubjectsCompletedNCT02171000Phase 1
• Bioavailability of BIBR 953 ZW After BIBR 1048 (Oral Pro-drug of BIBR 953 ZW) Administered as Hydroxypropyl Methylcellulose (HPMC) Polymorph II Capsule Relative to HPMC Polymorph I Capsule in Healthy Subjects.CompletedNCT02170974Phase 1
• Pharmacokinetic (PK) Assessment of BIBR 1048 in Patients After Primary Elective Total Hip Replacement SurgeryCompletedNCT02170935Phase 2
• Bioavailability of BIBR 1048 MS Tablets in Healthy Subjects With or Without FoodCompletedNCT02170922Phase 1
• Safety, Pharmacokinetics and Pharmacodynamics of BIBR 1048 MS Capsule in Healthy Male Subjects of Japanese and Caucasian OriginCompletedNCT02170909Phase 1
• Bioavailability of BIBR 963 ZW After 50 mg of BIBR 1048 MS With and Without of Pantoprazole in Healthy SubjectsCompletedNCT02170896Phase 1
• Safety, Pharmacokinetics and Pharmacodynamics After Single Rising Oral Doses of BIBR 1048 MS as Capsules in Healthy Subjects of Japanese and Caucasian OriginCompletedNCT02170844Phase 1
• Multiple Oral Doses of BIBR 1048 MS Solution in Healthy VolunteersCompletedNCT02170831Phase 1
• Bioavailability of BIBR 953 ZW in Healthy SubjectsCompletedNCT02170766Phase 1
• Assessment of Safety, Pharmacokinetics and the Effect of BIBR 1048 MS on Coagulation Parameters in Healthy Volunteer SubjectsCompletedNCT02170740Phase 1
• BIBR 1048 in the Prevention of Venous Thromboembolism in Patients Undergoing Primary Elective Total Hip Replacement SurgeryCompletedNCT02170701Phase 2
• Relative Bioavailability of Single Doses of Dabigatran Etexilate When Administered Alone or in Combination With a Single Dose of Ketoconazole or in Combination With q.d. Ketoconazole at Steady State in Healthy Male and Female VolunteersCompletedNCT02170675Phase 1
• Bioavailability of BIBR 953 ZW After Oral Administration of BIBR 1048 MS in Healthy SubjectsCompletedNCT02170636Phase 1
• Bioavailability of BIBR 953 ZW After Administration of BIBR 1048 MS in Healthy SubjectsCompletedNCT02170623Phase 1
• Bioavailability of BIBR 953 ZW Under Influence of Food in Healthy SubjectsCompletedNCT02170597Phase 1
• Tolerability of BIBR 953 ZW IV and Bioavailability of BIBR 1048 Tablet and Solution in Healthy MalesCompletedNCT02170584Phase 1
• Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic FunctionCompletedNCT02170571Phase 1
• Pharmacodynamics, Safety and Pharmacokinetics After Oral Administration of BIBR 1048 MS in Healthy VolunteersCompletedNCT02170116Phase 1
• Drug Interaction Study Between Bosutinib And DabigatranCompletedNCT02102633Phase 1
• Comparison of Blood Loss Following Total Hip Arthroplasty With the Use of Three Thromboprophylactic Regimes: Dabigatran, Enoxaparin and Rivaroxaban.Status unknownNCT02085824Not applicable
• Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial FibrillationCompletedNCT02067182Phase 4
• Cognitive Impairment Related to Atrial Fibrillation Prevention TrialCompletedNCT01994265Phase 4
• Direct Thrombin Inhibitors Versus LMWH in Staphylococcus Aureus BacteraemiaCompletedNCT01911624Phase 2
• Antithrombotic Triple Therapy in HumansCompletedNCT01812200Phase 4
• Pharmacokinetics, Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 2 Years of AgeWithdrawnNCT01773174Phase 2
• Dabigatran Treatment Following Transient Ischemic Attack and Minor StrokeCompletedNCT01769703Phase 2
• Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic EventsCompletedNCT01675076Phase 3
• Management of Myocardial Injury After Noncardiac Surgery TrialCompletedNCT01661101Phase 3
• Early Versus Late DC-cardioversion of Persistent Atrial Fibrillation. Effect on Atrial Remodeling,Inflammatory and Neurohumoral Markers and Recurrence of Atrial FibrillationCompletedNCT01593150Not applicable
• An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate in Hemodialysis PatientsCompletedNCT01590823Phase 1
• Reversal of the Antithrombotic Action of New Oral AnticoagulantsStatus unknownNCT01478282Phase 4
• DAPPAR AF Dabigatran for Peri Procedural Anticoagulation During Radiofrequency Ablation of Atrial FibrillationCompletedNCT01468155Phase 4
• Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty SurgeryCompletedNCT01431456Phase 3
• A Study to Investigate Biomarkers After Single Doses of Anticoagulants in Healthy Young Male and Healthy Elderly Participants (MK-0000-216 AM1)CompletedNCT01379300Phase 1
• Safety Study of Dabigatran in CADASILStatus unknownNCT01361763Phase 2
• Impact of Dabigatran and Phenprocoumon on Clopidogrel Mediated ADP Induced Platelet Aggregation in Patients With Atrial FibrillationTerminatedNCT01352702Phase 4
• Impact of Dabigatran and Phenprocoumon on ADP Induced Platelet Aggregation in Patients With Atrial FibrillationCompletedNCT01339819Phase 4
• Study in Healthy Volunteers of the Reversion by Haemostatic Drugs of the Anticoagulant Effect of New Anti-thromboticsCompletedNCT01210755Phase 4
• A Cohort Study With 100 Subjects Having a Primary Total Knee Replacement, Taking Pradax Post Discharge for Ten DaysWithdrawnNCT00868179Phase 4

← Dabigatran overview